H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report) today and set a price target of $26.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily driven by the promising results from the CheMo4METPANC Phase 2 trial. The trial, which evaluated motixafortide in combination with cemiplimab and standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), demonstrated impressive overall response and disease control rates.
The trial’s results showed a significant improvement over historical controls, with an overall response rate of 64% and a disease control rate of 91%, compared to 23% and 48% respectively. Additionally, the data indicated that some patients experienced prolonged progression-free survival and even underwent definitive treatments, suggesting potential durability of response. These encouraging findings position BioLine RX well for further trials and support the potential broader applicability of motixafortide in treating mPDAC.
According to TipRanks, Pantginis is an analyst with an average return of -20.5% and a 27.15% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Esperion, and Actinium Pharmaceuticals.